The New England Journal of Medicine has published a detailed analysis of Genentech’s positive results from the Phase III REGENCY study of Gazyva® (Obinutuzumab) for people with active lupus nephritis ...

The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene ...

In a new study published in Lupus Science & Medicine, researchers assessed clinical trial perceptions among a predominantly Black cohort of participants with systemic lupus erythematosus (SLE).

Black History Month is a time to honor the strength, resilience, and contributions of the Black community. This year, we’re focusing on the theme “Your Voice, Your Power” to highlight the importance ...

The way we talk about lupus – to ourselves and with others – matters. Living with lupus can feel like a daily battle filled with uncertainty. Negative self-talk about this disease and its limitations ...

Hydroxychloroquine is a key medicine for people with lupus, and you need to take it for a long time. HCQ-SAFE© is an interactive picture guide that will help you understand how the medicine ...

The treatment of lupus is particularly complex for young patients who must commit to lifelong Hydroxychloroquine therapy, which carries a chance, although low, of eye toxicity. Patients often face ...